Shares of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) are plummeting today, down 13% at $389.21, after the biotech company's non-opioid painkiller, Suzetrigine, matched the placebo in a phase 2 study. The stock is trading at 52-week lows after the news, earlier falling as low as $377.85, and headed for its worst single-day percentage loss since October 2020. Today's drop has VRTX breaking below support at the $445 level, which has been in place since early October, and dropping into negative territory for 2024 ...

Key TakeawaysVertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which causes leg and back pain.The company said the trial of suzetrigine met its primary endpoint in reducing pain, but a placebo reference arm also showed a "similar within-group reduction from baseline in pain."With Thursday's losses, Vertex shares fell into negative territory for the year. Vertex Pharmaceuticals (VRTX) shares sank Thursday mor ...

Core Insights - Vertex, Inc. has been recognized as a Leader in three IDC MarketScape reports for its tax technology solutions, highlighting its strong position in the market [1] - The recognition underscores Vertex's commitment to empowering businesses with advanced tax technology to navigate complex compliance requirements [1] - Vertex's innovative solutions are designed to support diverse industries and ensure accurate tax determination while integrating with evolving business models [1] Company Overview - Vertex, Inc. is a leading global provider of indirect tax solutions, focusing on delivering trusted tax technology for businesses to transact, comply, and grow confidently [4][5] - The company offers tailored solutions for various lines of indirect tax, including sales and consumer use, value-added tax, and payroll [5] - Vertex employs over 1,500 professionals and operates in North America, South America, and Europe, serving a global clientele [5] Industry Context - The IDC MarketScape vendor assessment model evaluates the competitive fitness of technology and service suppliers, providing a framework for comparing vendors based on qualitative and quantitative criteria [3] - The recognition from IDC emphasizes the importance of intelligent, automated tax management tools for businesses facing global tax complexities [2]

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying strong candidates can be challenging due to associated risks and volatility [1] Group 1: Vertex's Growth Potential - Vertex (VERX) is highlighted as a recommended growth stock with a favorable Growth Score and a top Zacks Rank [2] - The historical EPS growth rate for Vertex is 25.6%, with projected EPS growth of 59% this year, significantly surpassing the industry average of 30.1% [4] - Vertex's year-over-year cash flow growth is 21.3%, compared to an industry average of -14.4%, indicating strong cash flow performance [5] Group 2: Cash Flow and Historical Performance - The annualized cash flow growth rate for Vertex over the past 3-5 years is 42.8%, well above the industry average of 15.2% [6] - Positive trends in earnings estimate revisions have been observed, with the Zacks Consensus Estimate for the current year increasing by 11.1% over the past month [7] Group 3: Overall Assessment - Vertex has achieved a Growth Score of A and a Zacks Rank 2, reflecting positive earnings estimate revisions and strong growth metrics [9] - This combination positions Vertex as a potential outperformer and a solid choice for growth investors [11]

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

Have you been paying attention to shares of Vertex (VERX) ? Shares have been on the move with the stock up 28.9% over the past month. The stock hit a new 52-week high of $55.52 in the previous session. Vertex has gained 104.7% since the start of the year compared to the 29.2% move for the Zacks Computer and Technology sector and the 34.2% return for the Zacks Internet - Software industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed ...

Shares of Vertex, Inc. (VERX) , a leader in tax compliance and automation software, have skyrocketed 105% year to date (YTD). This impressive rally has placed Vertex among the top performers in the broader technology sector, vastly outperforming both the Zacks Internet - Software industry and The Technology Select Sector SPDR Fund (XLK) ETF, which posted gains of 32.6% and 22%, respectively.YTD Price Return PerformanceImage Source: Zacks Investment ResearchWhile such a rally raises questions about the stock ...

Vertex Pharmaceuticals (NASDAQ: VRTX ) reported better than expected earnings on the 4th of November with the stock surging over 5%. The company beat both revenue and earnings estimates, while raising its 2024 guidance, as sales increased 12% on a year-over-year basis. The short-lived rallyBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (T ...

Vertex (VERX) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.Analysts' growing optimism on the earnings prospects of this company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-t ...